[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100612843":3},{"organization":4,"armGroups":7,"interventions":32,"overallOfficials":47,"centralContacts":51,"locations":60,"responsibleParty":213,"collaborators":38,"id":215,"slug":216,"hasResults":217,"nctId":218,"briefTitle":219,"officialTitle":220,"acronym":38,"eligibilityCriteria":221,"healthyVolunteers":222,"sex":223,"minAge":224,"maxAge":225,"enrollmentInfo":226,"targetDuration":38,"studyType":229,"phases":230,"briefSummary":232,"conditions":233,"keywords":38,"overallStatus":63,"whyStopped":38,"lastUpdateSubmitDate":235,"lastUpdatePostDateStruct":236,"startDateStruct":239,"completionDateStruct":241,"leadSponsor":243,"locationsCount":244},{"fullName":5,"class":6},"Eli Lilly and Company","INDUSTRY",[8,14,20,24,28],{"label":9,"type":10,"description":11,"interventionNames":12},"LY4213663 (Part A)","EXPERIMENTAL","Single-ascending dose (SAD) of LY4213663 administered subcutaneously (SC) and intravenously (IV) in healthy participants",[13],"Drug: LY4213663",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo (Part A)","PLACEBO_COMPARATOR","SAD placebo administered SC and IV",[19],"Drug: Placebo",{"label":21,"type":10,"description":22,"interventionNames":23},"LY4213663 (Part B)","Multiple-ascending doses (MAD) of LY4213663 administered SC and IV in healthy participants",[13],{"label":25,"type":16,"description":26,"interventionNames":27},"Placebo (Part B)","MAD placebo administered SC and IV",[19],{"label":29,"type":10,"description":30,"interventionNames":31},"LY4213663 (Parts C and D)","Multiple doses of LY4213663 administered SC and IV in participants with RA",[13],[33,39,42,45],{"type":34,"name":35,"description":36,"armGroupLabels":37,"otherNames":38},"DRUG","LY4213663","Administered SC",[9,21,29],null,{"type":34,"name":35,"description":40,"armGroupLabels":41,"otherNames":38},"Administered IV",[9,21,29],{"type":34,"name":43,"description":36,"armGroupLabels":44,"otherNames":38},"Placebo",[15,25],{"type":34,"name":43,"description":40,"armGroupLabels":46,"otherNames":38},[15,25],[48],{"name":49,"affiliation":5,"role":50},"Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC\u002FGMT - 5 hours, EST)","STUDY_DIRECTOR",[52,57],{"name":53,"role":54,"phone":55,"phoneExt":38,"email":56},"Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or","CONTACT","1-317-615-4559","LillyTrials@Lilly.com",{"name":58,"role":54,"phone":38,"phoneExt":38,"email":59},"Physicians interested in becoming principal investigators please contact","clinical_inquiry_hub@lilly.com",[61,81,96,111,125,139,153,167,181,196],{"facility":62,"status":63,"city":64,"state":65,"zip":66,"country":67,"countryCode":68,"cosmosGeoPoint":69,"geoPoint":74,"contacts":75},"Pinnacle Research Group, LLC","RECRUITING","Anniston","Alabama","36207","United States","US",{"type":70,"coordinates":71},"Point",[72,73],-85.83163,33.65983,{"lat":73,"lon":72},[76,78],{"name":38,"role":54,"phone":77,"phoneExt":38,"email":38},"256-236-0055, ext 101",{"name":79,"role":80,"phone":38,"phoneExt":38,"email":38},"Vishala Chindalore","PRINCIPAL_INVESTIGATOR",{"facility":82,"status":63,"city":83,"state":84,"zip":85,"country":67,"countryCode":68,"cosmosGeoPoint":86,"geoPoint":90,"contacts":91},"Arizona Research Center","Phoenix","Arizona","85053",{"type":70,"coordinates":87},[88,89],-112.07404,33.44838,{"lat":89,"lon":88},[92,94],{"name":38,"role":54,"phone":93,"phoneExt":38,"email":38},"602-773-3020",{"name":95,"role":80,"phone":38,"phoneExt":38,"email":38},"Louise Taber",{"facility":97,"status":63,"city":98,"state":99,"zip":100,"country":67,"countryCode":68,"cosmosGeoPoint":101,"geoPoint":105,"contacts":106},"Clinical Research of West Florida, Inc. (Clearwater)","Clearwater","Florida","33765",{"type":70,"coordinates":102},[103,104],-82.8001,27.96585,{"lat":104,"lon":103},[107,109],{"name":38,"role":54,"phone":108,"phoneExt":38,"email":38},"727-466-0078",{"name":110,"role":80,"phone":38,"phoneExt":38,"email":38},"Robert Levin",{"facility":112,"status":63,"city":113,"state":99,"zip":114,"country":67,"countryCode":68,"cosmosGeoPoint":115,"geoPoint":119,"contacts":120},"GNP Research at Mark Jaffe, MD","Cooper City","33024",{"type":70,"coordinates":116},[117,118],-80.27172,26.05731,{"lat":118,"lon":117},[121,123],{"name":38,"role":54,"phone":122,"phoneExt":38,"email":38},"754-248-3589",{"name":124,"role":80,"phone":38,"phoneExt":38,"email":38},"Mark Jaffe",{"facility":126,"status":63,"city":127,"state":99,"zip":128,"country":67,"countryCode":68,"cosmosGeoPoint":129,"geoPoint":133,"contacts":134},"Fortrea Clinical Research Unit","Daytona Beach","32117",{"type":70,"coordinates":130},[131,132],-81.02283,29.21081,{"lat":132,"lon":131},[135,137],{"name":38,"role":54,"phone":136,"phoneExt":38,"email":38},"866-429-3700",{"name":138,"role":80,"phone":38,"phoneExt":38,"email":38},"Sharrell Cooper",{"facility":140,"status":63,"city":141,"state":99,"zip":142,"country":67,"countryCode":68,"cosmosGeoPoint":143,"geoPoint":147,"contacts":148},"AGA Clinical Trials","Hialeah","33012",{"type":70,"coordinates":144},[145,146],-80.27811,25.8576,{"lat":146,"lon":145},[149,151],{"name":38,"role":54,"phone":150,"phoneExt":38,"email":38},"704-526-6864",{"name":152,"role":80,"phone":38,"phoneExt":38,"email":38},"WILSON CUEVA",{"facility":154,"status":63,"city":155,"state":99,"zip":156,"country":67,"countryCode":68,"cosmosGeoPoint":157,"geoPoint":161,"contacts":162},"Advanced Pharma CR, LLC","Miami","33417",{"type":70,"coordinates":158},[159,160],-80.19366,25.77427,{"lat":160,"lon":159},[163,165],{"name":38,"role":54,"phone":164,"phoneExt":38,"email":38},"305-220-2727, Ext 802",{"name":166,"role":80,"phone":38,"phoneExt":38,"email":38},"Simon Abelson",{"facility":168,"status":63,"city":169,"state":99,"zip":170,"country":67,"countryCode":68,"cosmosGeoPoint":171,"geoPoint":175,"contacts":176},"Floridian Clinical Research","Miami Lakes","33016",{"type":70,"coordinates":172},[173,174],-80.30866,25.90871,{"lat":174,"lon":173},[177,179],{"name":38,"role":54,"phone":178,"phoneExt":38,"email":38},"305-330-9977",{"name":180,"role":80,"phone":38,"phoneExt":38,"email":38},"Christopher Mesa",{"facility":182,"status":63,"city":183,"state":184,"zip":185,"country":67,"countryCode":68,"cosmosGeoPoint":186,"geoPoint":190,"contacts":191},"Oasis Clinical Research","Las Vegas","Nevada","89121",{"type":70,"coordinates":187},[188,189],-115.13722,36.17497,{"lat":189,"lon":188},[192,194],{"name":38,"role":54,"phone":193,"phoneExt":38,"email":38},"702-832-1369",{"name":195,"role":80,"phone":38,"phoneExt":38,"email":38},"Stephen Tam",{"facility":197,"status":198,"city":199,"state":38,"zip":200,"country":201,"countryCode":202,"cosmosGeoPoint":203,"geoPoint":207,"contacts":208},"Universitätsklinikum Charité","NOT_YET_RECRUITING","Berlin","10117","Germany","DE",{"type":70,"coordinates":204},[205,206],13.41053,52.52437,{"lat":206,"lon":205},[209,211],{"name":38,"role":54,"phone":210,"phoneExt":38,"email":38},"+49 30 450 539 200",{"name":212,"role":80,"phone":38,"phoneExt":38,"email":38},"Stanislav Ignatenko",{"type":214,"investigatorFullName":38,"investigatorTitle":38,"investigatorAffiliation":38,"oldNameTitle":38,"oldOrganization":38},"SPONSOR","100612843","phase-1-a-study-of-ly4213663-in-healthy-participants-and-participants-with-rheumatoid-arthritis-100612843",false,"NCT07258849","A Study of LY4213663 in Healthy Participants and Participants With Rheumatoid Arthritis","A Phase 1, Multicenter, Randomized, Placebo-Controlled, Investigator- and Participant-Blinded, Single- and Multiple-Ascending Dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of LY4213663 in Healthy Participants, and Two Open-Label, Multiple-Dose Evaluations of LY4213663 in Patients With Rheumatoid Arthritis.","Inclusion Criteria:\n\n* Have a body mass index (BMI) of 18.0 to 32.0 kilogram per square meter (kg\u002Fm²), inclusive\n\nPart C and D Only:\n\n* Have a body weight at least 50 kilograms and BMI within the range 18.0 to 40.0 kg\u002Fm² (inclusive) at screening\n* Have a diagnosis of adult-onset RA for at least 3 months prior to screening\n\nExclusion Criteria:\n\nHealthy Participants for SAD Part A and MAD Part B Only:\n\n* Have a history or presence of cardiovascular, respiratory, hepatic, ophthalmological, renal, gastrointestinal, endocrine, hematological, neurological, or psychiatric disorders capable of significantly altering the absorption, metabolism, or elimination of drugs\n\nParticipants with RA for Parts C and D Only:\n\n* Have Class 4 RA according to American College of Rheumatology (ACR) revised criteria\n* Have a 12-lead electrocardiogram (ECG) abnormality at screening\n* Have a current or recent acute active infection",true,"ALL","18 Years","75 Years",{"count":227,"type":228},141,"ESTIMATED","INTERVENTIONAL",[231],"PHASE1","The purpose of this study is to evaluate how well LY4213663 is tolerated and what side effects may occur in healthy participants and participants with rheumatoid arthritis (RA). The study drug will be administered either subcutaneously (SC) (under the skin) or intravenously (IV) (into a vein in the arm).\n\nBlood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. The study will last approximately 33 weeks excluding screening.",[234],"Rheumatoid Arthritis (RA)","2026-06-19",{"date":237,"type":238},"2026-06-23","ACTUAL",{"date":240,"type":238},"2025-12-02",{"date":242,"type":228},"2028-03",{"name":5,"class":6},10]